Epitope specificity and isotype of CD40 agonist antibodies contribute to their function and clinical activity [14,22,23,24]. CD40 agonist antibodies are able to induce CD40 signaling to various degrees whether or not they block natural ligand binding. Studies using anti-mouse CD40 antibodies have ...
We conducted a multi-center, open label clinical trial to evaluate the combination of APX005M with nivo and standard chemotherapy (gem and NP). Herein, we report safety and efficacy from the ongoing study.Methods: Pts with previously untreated PDAC were enrolled in 4 cohorts: Gem/NP/APX005M...
9Sarah A. WeissMario SznolMontaser ShaheenMiguel-ngel Berciano-GuerreroEva Munoz CouseloDelvys Rodríguez-AbreuValentina BoniLynn M. SchuchterMaria Gonzalez-CaoAna AranceClinical Cancer Research
Acknowledgements We extend our gratitude to the patients and their families who made this trial possible and the clinical study teams involved in this trial. We thank BMS for providing the nivolumab for this study. Trial Registration NCT03123783 Ethics Approval This study was approved by the ...
The clinical development of CD40 agonist antibodies requires careful optimization of the antibody to maximize therapeutic efficacy while minimizing adverse effects. Both epitope specificity and isotype are critical for CD40 agonist antibody mechanism of action and potency. We developed a novel antibody, ...
Sotigalimab is a CD40 agonist antibody with unique epitope specificity and Fc-receptor binding profile optimized for activation of CD40-expressing antigen ... S Weiss,M Sznol,M Shaheen,... - 《Clinical Cancer Research An Official Journal of the American Association for Cancer Research》 被引量...